DCGI Approves Akums Pharma To Launch Diabetes Drug Lobeglitazone In India
Akums Drugs and Pharmaceuticals has been approved by the Drugs Controller-General of India (DCGI) to boost to the treatment of type 2 diabetes with the launch of the novel antidiabetic drug ‘Lobeglitazone’.
The drug released by the company, is a new formulation manufactured specifically for type 2 diabetic patients by helping them improve pancreatic beta-cell function.
The drug was formulated for type 2 diabetics who secrete insulin but have poor insulin sensitivity in their organs, making them less able to utilise insulin. Lobeglitazone is a one-of-a-kind medication which has a relatively low risk of hypoglycemia. The formulation was manufactured to improve insulin resistance rather than force its release from the pancreas.
"This novel product is the result of in-depth research and development and tireless commitment to the production of new drug formulations for the Indian market. The tablet has been proven to reduce blood sugar levels, improve lipid and liver profiles, and lower haemoglobin A1C (HbA1C) levels. The fact that we're the first CDMO to do this tells a lot about our focus on innovation to offer more effective treatment for the patients," said Sanjeev Jain, Managing Director of Akums.
He said, "It's important that we as drug manufacturers continue to innovate to provide more effective solutions to ailments and diseases. With the Lobeglitazone tablets, what we've put together is a unique formulation that tackles type 2 diabetes by addressing the root causes in a more effective way; by affecting the relationship between the PPAR gamma, insulin, and fat cells to improve insulin resistance, among other things."
Lobeglitazone is approved by the Drugs Controller-General of India (DCGI) and offers a number of advantages, including higher safety profile, higher effectiveness in lower dosage, lower risk of hypoglycemia, and improved pancreatic beta-cell function, among others.
The new formulation is a step further in their attempt to make treatment and management of diabetes more accessible and easier. It is a safe and well-tolerated formulation that offers repose to diabetic patients. The company also plans to introduce more fixed dose drug combinations (FDCs) in the future specifically for the treatment and management of diabetes, even as it continues to be a major player in the Indian pharma industry.
